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Abstract
Background: Parkinson's disease, a prevalent neurodegenerative disease, is characterized by the
reduction of dopaminergic neurons resulting in the loss of motor control, resting tremor, the
formation of neuronal inclusions and ultimately premature death. Two inherited forms of PD have
been linked to mutations in the α-synuclein and parkin genes. The parkin protein functions as an
ubiquitin ligase targeting specific proteins for degradation. Expression of human α-synuclein in
Drosophila neurons recapitulates the loss of motor control, the development of neuronal inclusions,
degeneration of dopaminergic neurons and the ommatidial array to provide an excellent genetic
model of PD.
Results: To investigate the role of parkin, we have generated transgenic Drosophila that
conditionally express parkin under the control of the yeast UAS enhancer. While expression of
parkin has little consequence, co-expression of parkin with α-synuclein in the dopaminergic neurons
suppresses the α-synuclein-induced premature loss of climbing ability. In addition directed
expression of parkin in the eye counteracts the α-synuclein-induced degeneration of the ommatidial
array. These results show that parkin suppresses the PD-like symptoms observed in the α-
synuclein-dependent Drosophila model of PD.
Conclusion: The highly conserved parkin E3 ubiquitin ligase can suppress the damaging effects of
human α-synuclein. These results are consistent with a role for parkin in targeting α-synuclein to
the proteasome. If this relationship is conserved in humans, this suggests that up-regulation of
parkin should suppress α-synucleinopathic PD. The development of therapies that regulate parkin
activity may be crucial in the treatment of PD.
Background
Parkinson's disease (PD) is a neurodegenerative disorder
that is characterized by muscle tremors in stationary
limbs, bradykinesia (slowed movement) and difficulty
initiating and sustaining movements, and affects 1–2% of
the population older than sixty years of age [1-5]. As the
disease progresses, both the sense of balance and the
memory of the affected individual deteriorate. Post-mor-
tem analysis reveals the selective loss of dopaminergic
neurons from the substantia nigra region of the brain. Fil-
amentous protein inclusions, known as Lewy bodies, are
found within the neuronal cell bodies of the affected area,
in most but not all PD patients [4]. Although the majority
of PD cases appear to be sporadic, about 5–15% have
been determined to have an inherited basis [6,7].
Recently, mutations in a number of genes have been
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associated with the ubiquitin/proteasome protein degra-
dation pathway.
Mutations in the gene encoding the α-synuclein protein
lead to the development of Autosomal Dominant PD
(ADPD) [8,9]. The α-synuclein protein is an abundant
140 amino acid, cytosolic protein found at the pre-synap-
tic region of neurons [10,11]. α-synuclein appears to be
involved in the biosynthesis of dopamine [12,13]. Muta-
tions in the α-synuclein gene [8,9] may lead to enhanced
oligomerization and fibril formation of the α-synuclein
protein [14-16].
Autosomal Recessive Juvenile Parkinson's disease (ARJP),
another inherited form of PD, has been attributed to a
number of point mutations and deletions of the parkin
gene [17-19]. ARJP is specifically characterized by a very
early age of onset, mostly before forty years of age, and the
absence of Lewy bodies [20-22]. In humans, the parkin
gene encodes a 465 amino acid protein [17] that func-
tions as one of a number of E3 ubiquitin protein ligases,
components of the ubiquitin/proteasome degradation
pathway [23]. Ubiquitin protein ligases act to identify
damaged, misfolded, and short-lived proteins to mediate
the ubiquitination (the sequential attachment of a
number of ubiquitin monomers) of these proteins, which
are targeted to the proteasome [24,25]. Experiments in tis-
sue culture have demonstrated that parkin can ubiquiti-
nate a number of substrates including a glycosylated form
of α-synuclein [26], the Pael receptor [27], CDCrel-1 [28],
the α-synuclein-binding protein synphilin-1 [29], and
parkin itself [28,30]. The loss of parkin may lead to an
accumulation of one or a number of proteins in sufficient
quantities to cause neuronal cell death.
The interaction of parkin with α-synuclein suggests a com-
mon mechanism underlying inherited forms of PD.
Indeed, elevated expression of parkin protects neuronal
explants from the toxicity associated with expression of α-
synuclein [26,31]. The disease inducing-forms of α-synu-
clein may prevent its degradation and result in toxic accu-
mulation. In ARJP, functional parkin protein is lost along
with the ability to mediate the ubiquitination of glyco-
sylated α-synuclein and may lead to the accumulation of
this protein [26]. Our working hypothesis is that aspects
of parkin-mediated protein degradation are compromised
in PD.
The first Drosophila melanogaster model of PD was gener-
ated by the conditional expression of human α-synuclein
in transgenic Drosophila [32]. Flies that express α-synuclein,
in either a pan-neural or dopaminergic neuron specific
manner, show a marked age-dependent loss of dorsal-
medial dopaminergic neurons. Cytoplasmic inclusions
were observed in α-synuclein-expressing flies approxi-
mately 20 days after eclosion. While control flies exhibit a
strong negative geotaxis, these transgenic flies prema-
turely lose their climbing ability. In addition, expression
of α-synuclein in the developing eye results in precocious
degeneration of the retina. In this model expression of a
number of genes are dysregulated prior to the onset of
neurodegeneration [33]. These features recapitulate the
main behavioural and pathological phenotypes of PD and
provide an excellent model system to study the biological
basis of the disease.
The Drosophila α-synuclein based model has been used to
investigate a number of aspects of PD. Pharmacological
agents, such as the dopamine precursor levodopa,
dopamine receptor agonists (bromocriptine, pergolide
and SK&F38393), and the anticholinergic atropine, were
demonstrated to modify the age-dependent loss of climb-
ing ability [34]. Co-expression of the molecular chaper-
one HSP70 gene with α-synuclein prevented dopaminergic
neuronal degeneration [35]. Interference with endog-
enous chaperone activity accelerated the toxicity of α-
synuclein demonstrating a role for chaperones in the
pathology of the disease. Suppression of HSP90, a nega-
tive regulator of the heat shock factor 1, by feeding flies
geldanamycin prevents dopaminergic neuronal cell death
[36]. Recently, the expression of human parkin has been
shown to suppress the loss of dopaminergic neurons
induced by α-synuclein in Drosophila [37]. This model has
proven to be an effective tool in the investigation of the
biological basis of PD.
To investigate the role of parkin in the α-synuclein-based
model of Parkinson's disease in Drosophila, we have char-
acterized and expressed the Drosophila homologue of par-
kin in this model. Our results demonstrate that parkin can
counteract the effects of α-synuclein on climbing activity
and retinal degeneration.
Results
Characterization of Drosophila melanogaster parkin
The Drosophila melanogaster parkin homologue was identi-
fied through a search of the Berkeley Drosophila Genome
Project (BDGP) utilizing the tBlastn search algorithm. The
parkin gene is located on the left arm of the third chromo-
some, in the polytene chromosome section 78C within
the genomic scaffolding region AE003593 (BDGP), and
consists of 6 exons over 2.2 kb (Figure 1A). A search of the
genome for additional parkin homologues revealed none.
Our analysis confirmed the sequence of parkin to be iden-
tical to that reported by the BDGP (AY058754.1). Two
potential initiation codons for the parkin protein are sep-
arated by 42 base pairs at the 5' region of the transcript. As
the second potential start codon is preceded by CAAA, a
match to the Drosophila Kozak consensus sequence (C/Page 2 of 12
(page number not for citation purposes)
BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/14A)AA(A/C)ATG) of translation initiation [38], we have
assigned this as the most likely start codon. Furthermore,
of the preceding fourteen potential codons only two use
preferred codons [39] (data not shown). The Drosophila
parkin gene was reported by Greene and colleagues [40],
while the current experiments were being conducted.
The parkin protein is well conserved
The Drosophila melanogaster parkin protein has been
reported to be 42% identical to human parkin [40] (Fig-
ure 1B). Parkin protein homologues were identified from
Rattus norvegicus (NM_020093.1) and Mus musculus
(AB019558.1) via the tblastn algorithm of the National
Center for Biotechnology Information (NCBI). Both the
R. norvegicus and M. musculus homologues were found to
have 44% identity and 60% similarity to D. melanogaster
parkin when analysed by the blast2 algorithm (Figure 1B).
In addition, we have determined that the Anopheles gam-
biae sequence XM316606.1 [41] is a homologue of parkin.
Like D. melanogaster, the A. gambiae transcript has two
Dipteran and mammalian parkin proteins are well conservedFigure 1
Dipteran and mammalian parkin proteins are well conserved. (A) Schematic representation of the Drosophila mela-
nogaster parkin transcription unit and its location in the genomic scaffolding region AE003593. (B) ClustalW alignment of the 
Drosophila melanogaster parkin with homologues from Anopheles gambiae, Rattus norvegicus, Mus musculus and Homo sapiens. 
Highlighted are the Ubiquitin-like Domain (UBL) (green box); the Unique Parkin Domain (UPD) (red box); RING1 and RING2 
(blue boxes); In-Between Ring Domain (IRB) (black box). "*" and red lettering indicates amino acids that are identical in all 
sequences in the alignment. ":" and green lettering indicates conserved substitutions. "." and blue lettering indicates semi-con-
served substitutions.
D. melanogaster MLELLQFGGKTLTHTLSIYVKTNTGKTLTVNLEPQWDIKNVKELVAPQLGLQPDDLKIIFAGKELSDATTIEQCDLGQQSVLHAIRLRP-------- PV 92
A. gambiae      MLAIFSFGKKKLSNSLSVYVKTNTGNTLAVDLEPHMDIKDVKEMVAPRLGLEPQELKIIFAGRELSDTTTISECDLGQQSIIHVVKSRPT----AITTPQ 97
R. norvegieus ---------------MIVFVRFNSSYGFPVEVDSDTSIFQLKEVVAKRQGVPADQLRVIFAGKELQNHLTVQNCDLEQQSIVHIVQ-RPQRKSHETNASG 85
M. musculus ---------------MIVFVRFNSSYGFPVEVDSDTSILQLKEVVAKRQGVPADQLRVIFAGKELPNHLTVQNCDLEQQSIVHIVQ-RPRRRSHETNASG 85
H. sapiens ---------------MIVFVRFNSSHGFPVEVDSDTSIFQLKEVVAKRQGVPADQLRVIFAGKELRNDWTVQNCDLDQQSIVHIVQ-RPWRKGQEMNATG 85
                               : ::*: *:.  :.*:::.. .* ::**:** : *: .::*::****:** :  *:.:*** ***::* :: **         .
D. melanogaster QRQK--IQSATLEEE-EPSLSDEASKPLNETLLDLQLESEE-RLNITDEERVR----AKAHFFVHCS-QCDKLCNGKLRVRCALCKGGAFTVHRDPECWD 183
A. gambiae      KRQAKPALNATISEEPSPEEQQQHNKPLSETMSELTVLDE--RNGDQSIPIGR----TKAHFFVYCS-QCEKVCTGKLRVRCGICGSGAFTVHRDPTCWD 190
R. norvegieus   GDKPQSTPEGSIWEPRSLTRVDLSSHILPADSVGLAVILDTDSKSDSEAARGPAAKPTYHSFFVYCKGPCHKVQPGKLRVQCGTCRQATLTLAQGPSCWD 185
M. musculus     GDEPQSTSEGSIWESRSLTRVDLSSHTLPVDSVGLAVILDTDSKRDSEAARGP-VKPTYNSFFIYCKGPCHKVQPGKLRVQCGTCKQATLTLAQGPSCWD 184
H. sapiens      GDDPRNAAGGCEREPQSLTRVDLSSSVLPGDSVGLAVILHTDSRKDSPPAGSPAGRSIYNSFYVYCKGPCQRVQPGKLRVQCSTCRQATLTLTQGPSCWD 185
                  .      .   *  .    :  .  *      * :  .                     *:::*.  *.::  *****:*. *  .::*: :.* ***
D. melanogaster DVLKSRRIPGHCESLEVACVDNAAGDPPFAEFFFKCAEHVSGGEKDFAAPLNLIKNNFKNVPCLACTDVSDTVLVFPCASQHVTCIDCFRHYCRSRLGER 283
A. gambiae DVLKRKRITGHCENYEVPCVENDEGEPPFTEFYFKCSEHSSGGEKDFAAPLSLIKTNHKNIPCIACTDTSETILVFPCVAGHVSCLDCFRQYCVTRLLER 290
R. norvegieus DVLIPNRMSGECQSPDCPGTR--------AEFFFKCGAHPTS-DKDTSVALNLITNNSRSIPCIACTDVRNPVLVFQCNHRHVICLDCFHLYCVTRLNDR 275
M. musculus DVLIPNRMSGECQSPDCPGTR--------AEFFFKCGAHPTS-DKDTSVALNLITSNRRSIPCIACTDVRSPVLVFQCNHRHVICLDCFHLYCVTRLNDR 274
H. sapiens DVLIPNRMSGECQSPHCPGTS--------AEFFFKCGAHPTS-DKETPVALHLIATNSRNITCITCTDVRSPVLVFQCNSRHVICLDCFHLYCVTRLNDR 275
                ***  .*:.*.*:. . . .         :**:***. * :. :*: ...* ** .* :.:.*::***. ..:*** *   ** *:***: ** :** :*
D. melanogaster QFMPHPDFGYTLPCPAGCEHSFIEEIHHFKLLTREEYDRYQRFATEEYVLQAGGVLCPQPGCGMGLLVEPDCRKVTCQNG----CGYVFCRNCLQGYHIG 379
A. gambiae QFVEHPTGGYTLQCPAGCDNSFIEDVHHFKLLNKEQYERYQRFATEEFVLKNGGVLCPQPGCGMGLLVDPECRRIQCQNG----CGYVFCRSCLQGYHIG 386
R. norvegieus QFVHDAQLGYSLPCVAGCPNSLIKELHHFRILGEEQYNRYQQYGAEECVLQMGGVLCPRPGCGAGLLPEQGQRKVTCEGGNGLGCGFVFCRDCKEAYHEG 375
M. musculus QFVHDAQLGYSLPCVAGCPNSLIKELHHFRILGEEQYTRYQQYGAEECVLQMGGVLCPRPGCGAGLLPEQGQRKVTCEGGNGLGCGFVFCRDCKEAYHEG 374
H. sapiens QFVHDPQLGYSLPCVAGCPNSLIKELHHFRILGEEQYNRYQQYGAEECVLQMGGVLCPRPGCGAGLLPEPDQRKVTCEGGNGLGCGFAFCRECKEAYHEG 375
                **: ..  **:* * *** :*:*:::***::* .*:* ***::.:** **: ******:**** *** :   *:: *:.*    **:.***.* :.** *
D. melanogaster ECLPEGTGASATNSCEYTVDPNRAAEARWDEASNVTIKVSTKPCPKCRTPTERDGGCMHMVCTRAGCGFEWCWVCQTEWTRDCMGAHWFG- 468
A. gambiae ECFETPTPSTPGNEQGYAIDPLRASEARWDEATKIAIKVTTKPCPQCRTATERDGGCMHMVCTRSGCGFEWCWVCQTPWTRDCMAAHWFG- 475
R. norvegieus ECDSMFE-ASGATSQAYRVDQRAAEQARWEEASKETIKKTTKPCPRCNVPIEKNGGCMHMKCPQPQCKLEWCWNCGCEWNRACMGDHWFDV 464
M. musculus DCDSLLE-PSGATSQAYRVDKRAAEQARWEEASKETIKKTTKPCPRCNVPIEKNGGCMHMKCPQPQCKLEWCWNCGCEWNRACMGDHWFDV 463
H. sapiens ECSAVFE-ASGTTTQAYRVDERAAEQARWEAASKETIKKTTKPCPRCHVPVEKNGGCMHMKCPQPQCRLEWCWNCGCEWNRVCMGDHWFDV 464
:*      .:  .   * :*   * :***: *:: :** :*****:*... *::****** *.:. * :**** *   *.* **. ***.
A
B
Ubiquitin like domain (UBD)
Unique parkin domain (UPD)
RING1
Inbetween RING domain (IBR)
RING2
Unique parkin domain (UPD)
Kb
1 2 3 4 65
Genomic sequence
AE 003593
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sequence prior to the first ATG is very poor, however the
second site closely resembles the consensus sequence and
therefore it is very likely the start site. We determined that
the theoretical A. gambiae parkin protein has 65% identity
and 79% similarity to D. melanogaster parkin (Figure 1B).
The parkin protein appears to be highly conserved at the
amino acid sequence level.
Alignment of D. melanogaster parkin protein sequences
with the A. gambiae, R. norvegicus, M. musculus and H. sapi-
ens homologues reveals conservation of the protein
throughout a number of characteristic domains, including
the Ubiquitin- like Domain (UBL), the Unique Parkin
Domain (UPD), the Really Interesting New Gene finger 1
(RING1) domain, the In- Between Ring (IBR) domain,
and the RING2 domain (Figure 1B). In the amino-termi-
nal region of the proteins, the first 15 amino acids are well
conserved between A. gambiae and D. melanogaster, but
absent in the mammalian proteins. The human UBL
shows very high similarity (62%) to human ubiquitin
[17]. Correspondingly the Drosophila UBL (Figure 1B,
green box) was found to have 43% identity and 67% sim-
ilarity to Drosophila ubiquitin (AAA29007; data not
shown). The second highly conserved region is unique to
parkin and has been termed the unique parkin domain
(UPD) [42] (Figure 1B, red box). D. melanogaster and A.
gambiae share a similar eight amino acid insertion in the
UPD (Figure 1B). There are two RING-finger domains that
are defined by the consensus sequence C-X2-C-X9...39-C-
X1...3-H-X2...3-C/H-X2-C-X4...48-C-X2-C where X can be any
amino acid (Figure 1B, blue boxes) [43]. These RING-fin-
ger domains flank a cysteine-rich domain designated the
In-Between Ring (IBR) domain (Figure 1B, black box)
[44]. These three domains are responsible for binding to
specific E2 ubiquitin conjugating enzymes [23,28,30].
Between the RING1 and the IBR domains there is an eight-
een amino acid stretch of high conservation with the
sequence (N/H)S(L/F)I(K/E)(E/D)(I/L)HHF(K/R)(L/
I)LX(R/E)E(E/Q)Y. A 41 amino acid segment separates the
IBR and RING2 domains, and while the first half of this
segment is not well conserved the second half is highly
conserved with the sequence AX(E/Q)ARW(D/E)XA(S/
T)(N/K)X(T/A)IKX(S/T)TKP. The carboxy-terminus is well
conserved and has the following sequence M(G/
A)XHWF(G/D)(-/V), suggesting a possible conserved
function for the tail of the protein. As parkin undergoes
self-ubiquitination [28], conserved potential ubiquitina-
tion sites (lysine residues) were identified. There is a
lysine residue that is completely conserved at K-42 of the
dipterans and this corresponding residue is K-27 in mam-
mals (Figure 1B, black arrow). The mouse and rat parkin
homologues have been recently compared to Drosophila
parkin [45], however a number of the above features were
not discussed. Overall parkin appears to be highly con-
served between mammalian and dipteran species suggest-
ing conservation of function among these species.
parkin suppresses degeneration of the ommaditial array in 
flies that express α-synuclein in the eye
We generated stable transgenic flies that can conditionally
express parkin when the UAS/Gal4 expression system is
utilized [46]. In situ hybridization was used to confirm
parkin expression in transgenic Drosophila (data not
shown). Expression of parkin was directed to the develop-
ing eye using the GMR-Gal4 transgene resulting in no
obvious alteration of the eye (data not shown). In vitro
and cell culture research suggests that parkin can prevent
α-synuclein-induced toxicity [31,47]. Expression of human
α-synuclein in the Drosophila eye causes premature deterio-
ration of the retina [32]. To examine if parkin could pre-
vent α-synuclein-induced degeneration, we co-expressed
parkin with human α-synuclein in the developing eye.
Cross-sections of the retinas of one-day-old flies that
express α-synuclein appear to be intact, as previously
described (Figure 2A) [32]. The retinas of one-day-old
flies that express both α-synuclein and parkin also appear
normal (Figure 2B,2C). As previously described, the reti-
nas of thirty-day-old flies that express α-synuclein show
signs of premature degeneration [32]. Degeneration of the
normal architecture of the eye is apparent (Figure 2D,
black arrows) and reflects the disruption of the normal
placement and alignment of the photoreceptors and sup-
porting cells. In contrast, thirty-day-old flies that express
α-synuclein and parkin maintain their ommatidial arrays
and morphology (Figure 2E,2F). This observation demon-
strates that directed expression of parkin suppresses α-
synuclein-dependent degeneration of the ommatidial
array.
Retinal damage can be observed by examining an optical
effect termed the pseudopupil, which is lost in aged flies
that express α-synuclein [32]. We examined flies that co-
express α-synuclein and parkin, and there appeared to be
some retention of this optical effect compared with flies
that express α-synuclein alone (data not shown). Scanning
electron microscopy of eyes revealed no obvious deterio-
ration of the surface in flies that express α-synuclein (Fig-
ure 3A and 3D) or flies that co-express α-synuclein and
parkin (Figure 3B,3C,3E and 3F). Although α-synuclein
causes degeneration of the ommatidial array, the external
structure of the eye is unaffected.
Directed-expression of parkin to dopaminergic neurons 
does not affect climbing ability
Young wild-type adult Drosophila exhibit a strong negative
geotaxis, which is increased by mechanical stimulation
[48,49]. In order to measure climbing ability, flies are
placed in a vial, gently tapped to the bottom and allowed
to climb up the sides [32]. When parkin is expressed in thePage 4 of 12
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change in their climbing ability over their life span when
compared with controls (Figure 4A). In addition,
expression of parkin in dopaminergic neurons does not
alter life span (Figure 4B). These results demonstrate that
parkin expression in the dopaminergic neurons has little
effect upon climbing ability or life span.
Parkin suppresses α-synuclein induced loss of climbing 
ability
Flies that express α-synuclein, specifically in their
dopaminergic neurons through the activity of the Ddc-
Gal4 transgene, were assayed for their climbing ability
over their life span, and were found to prematurely lose
their climbing ability (Figure 5A). Co-expression of parkin
with α-synuclein suppresses this premature loss of climb-
ing ability (Figure 5A). This suggests that parkin can act to
prevent the deleterious effects of α-synuclein expression.
Aging assays were carried out in tandem with the climbing
assays described above in order to account for changes in
climbing ability as a result of premature senescence.
Median survival age for flies that express α-synuclein is
similar to flies that co-express α-synuclein with parkin (Fig-
ure 5B). This indicates that differences in climbing ability
were not due to differences in life span.
Discussion
Drosophila parkin has a high degree of similarity to the
mammalian and A. gambiae homologues. The five charac-
teristic domains of the parkin protein, the Ubiquitin- like
Domain (UBL), Unique Parkin Domain (UPD), Really
Interesting New Gene finger 1 (RING1) domain, In-
Between Ring (IBR) domain and RING2 all show a high
degree of similarity. In addition, the two dipterans, D.
melanogaster and A. gambiae, have a highly conserved extra
segment of 15 amino acids at the amino-terminal of the
protein. The regions between the three carboxy-terminus
domains are also highly conserved, which may indicate
conservation of function. Patients with ARJP caused by
mutations in the UBL domain exhibit signs of lost sub-
strate binding [23]. The UBL domain also appears to be
involved in binding the Rpn10 subunit of the 26S protea-
some as the R42P amino acid substitution in this domain
Expression of parkin suppresses α-synuclein-induced retinal degenerationFigure 2
Expression of parkin suppresses α-synuclein-induced retinal degeneration. Flies that express α-synuclein with and 
without parkin were aged to 1 or 30 days old. They were fixed and embedded in epon. Tangential sections (0.5 µm thick) of the 
retina were cut, stained with toludine blue and examined by light microscopy. Panels A-C represent one-day-old flies and pan-
els D-F represent thirty-day-old flies. Black arrows indicate degeneration of the ommatidial architecture. The genotypes are 
(A,D) w1118; UAS-α-synuclein/GMR-Gal4, (B,E) w1118; UAS-α-synuclein/GMR-Gal4; UAS-parkin1.1/+, and (C,F) w1118; UAS-α-synuclein/
GMR-Gal4; UAS-parkin2.1/+. Scale bar is 15 µm.Page 5 of 12
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proteasome binding of parkin (Figure 6) [50]. Alterations
of the RING1, RING2 and IBR domains of parkin result in
an almost complete loss of ubiquitin conjugating enzyme
H7 (UbcH7)-binding activity, which indicates that all
three domains are functionally important in recruiting
specific E2 ubiquitin conjugating enzymes [51]. The
RING1 and RING2 domains are thought to collaborate to
trap UbcH7 (Figure 6) [51]. Amino acid substitutions in
the RING1 domain change the subcellular localization of
parkin and enhance cytoplasmic and nuclear inclusions
[52]. In addition, the amino acid substitutions C289G
and C418R, which replace conserved cysteine residues in
the RING domains, significantly decrease the solubility of
parkin in cells [53]. Ubiquitination generally occurs near
the amino-terminus of proteins and ubiquitin monomers
are attached to lysine residues [25]. Several lysine residues
are absolutely conserved, including one in the UBL and
Expression of α-synuclein with and without parkin does not affect the external morphology of the eyeFigure 3
Expression of α-synuclein with and without parkin does not affect the external morphology of the eye. Scanning 
electron microscopy of flies that express α-synuclein with and without parkin shows no change in their external morphology 
over thirty days. Panels A-C represent one-day-old flies and panels D-F represent thirty-day-old flies. The genotypes are (A,D) 
w1118; UAS-α-synuclein/GMR-Gal4, (B,E) w1118; UAS-α-synuclein/GMR-Gal4; UAS-parkin1.1/+, and (C,F) w1118; UAS-α-synuclein/GMR-
Gal4; UAS-parkin2.1/+. Scale bar indicates 200 µm.Page 6 of 12
(page number not for citation purposes)
BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/14Expression of parkin does not affect climbing ability or life spanFigure 4
Expression of parkin does not affect climbing ability or life span. Panel A – Climbing ability of flies that express parkin 
does not differ from control flies. Genotypes are w1118; UAS-parkin1.1/Ddc-Gal4 (green open triangle), w1118; UAS-parkin2.1/Ddc-
Gal4 (orange open square) and w1118; Ddc-Gal4/+ (black open circles). The error bars show the standard error of the mean of 
twenty trials at each point. Please note that the error bars are mostly within the symbols. B – The life span of flies that express 
parkin does not differ from the control. The genotypes are marked the same as in panel A. The mortality of flies was examined 
every two days.Page 7 of 12
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Expression of parkin suppresses α-synuclein-induced loss of climbing ability. Panel A – Aged flies that express parkin 
and α-synuclein climb significantly better than flies that express α-synuclein (P < 0.001, one-way analysis of variance with supple-
mentary Newman-Keuls test). Genotypes are w1118; UAS-α-synuclein/+; Ddc-Gal4/+ (green open square), w1118; UAS-α-synuclein/
+; UAS-parkin1.1/Ddc-Gal4 (red open triangle), w1118; UAS-α-synuclein/+; UAS-parkin2.1/Ddc-Gal4 (blue upside down open triangle). 
The error bars show the standard error of the mean of twenty trials at each point. Please note that the error bars are mostly 
within the symbols. B – The life span of flies that express α-synuclein with and without parkin does not differ. The genotypes are 
marked the same as in panel A.Page 8 of 12
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tion. The existence of orthologues of mammalian parkin
in invertebrates but not plants nor fungi [54] suggest an
animal specific function for parkin activity. The highly
conserved protein domains and sub-domains suggest the
probable conservation of each domain's function, and
given the high degree of similarity we suggest that the
function of the Drosophila parkin protein is similar to that
of the human parkin protein.
We demonstrate that the directed expression of parkin in
the dopaminergic neurons and developing eyes leads to
no obvious adverse effects. The unaltered phenotype
observed when parkin is expressed in dopaminergic neu-
rons is likely due to substrate specificity and to the ability
of the parkin protein to target itself for degradation [28].
Under conditions of over-expression, parkin does not
seem to target and tag essential proteins for degradation
promiscuously. This may represent an excellent fail-safe
mechanism the cell has developed to balance the levels of
both parkin and its substrates.
The Drosophila model of ADPD has been used to examine
the effect of various pharmacological agents [34,36] and
other genetic aspects of the disease [35,37]. We expressed
parkin along with α-synuclein and found the suppression
Model of parkin directed ubiquitination of α-synucleinFigure 6
Model of parkin directed ubiquitination of α-synuclein. The parkin protein consists of two functionally distinct regions. 
The UBL/UPD region binds target proteins such as glycosylated α-synuclein. The RING-box (RING1-IBR-RING2) region 
recruits specific E2 ubiquitin conjugating enzymes, which add ubiquitin monomers to the target protein. In addition to substrate 
binding the UBL domain interacts with the proteasome. Ubiquitin tagged α-synuclein is directed to the proteasome and 
degraded into polypeptides and ubiquitin monomers. UBL – Ubiquitin-like Domain, UPD – Unique Parkin Domain, RING1 or 2 
– Really Interesting New Gene finger 1 or 2 domain, IBR – In-Between Ring domain.
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ture loss of climbing. These results indicate that parkin
may target α-synuclein for degradation in vivo (Figure 6).
Although coimmuno-precipitation studies have shown
that parkin does not interact with or ubiquitinate non-
modified α-synuclein [29], parkin will ubiquitinate O-
glycosylated α-synuclein [26]. Since we show suppression
of the α-synuclein-induced phenotype, we believe that
ectopically expressed α-synuclein is modified in Drosophila,
enabling its ubiquitination by parkin. The modification of
α-synuclein and subsequent ubiquitination by parkin is
presented in Figure 6.
In order to select rational potential therapeutic agents, the
molecular mechanisms behind disease progression must
be characterized. Gene function studies with homologues
of disease-causing genes in model organisms have been
made practical through the advent of genome projects.
Over-expression of parkin has no apparent adverse conse-
quences and it suppresses the α-synuclein-induced PD
symptoms in Drosophila. If this relationship is conserved
in humans, we suggest that up-regulation of parkin should
be a viable treatment for PD, and the selection of thera-
peutic strategies should be directed towards this end.
Conclusions
Our experiments demonstrate that the directed expression
of the parkin gene counteracts the PD-like symptoms in
the α-synuclein-induced Drosophila model of PD. Manipu-
lation of the ubiquitin/proteasome degradation pathway
in such a specific manner apparently remedies the toxic
accumulation of α-synuclein. This study demonstrates the
success of selective targeting of toxic proteins for degrada-
tion as an approach to address neurodegenerative condi-
tions such as Parkinson's disease. The development of
therapies that regulate parkin expression or parkin protein
activity may be crucial in the treatment of PD.
Methods
Bioinformatic and sequence analysis
The Drosophila melanogaster homologue of parkin was
identified through a search of the Berkeley Drosophila
Genome Project [55] queried with the human parkin
amino acid sequence, AB009973.1. A clone of the Dro-
sophila parkin cDNA (SD01679) was obtained from
Research Genetics [56], sub-cloned and sequenced
(Cortec DNA Service Laboratories Inc., Kingston, ON,
Canada). The intron/exon map was constructed by com-
parison of the cDNA to the corresponding genomic
region. Other homologues of parkin were identified with
the tblastn algorithm [57] of the National Center for Bio-
technology Information (NCBI) using the theoretical
translation of SD01679 cDNA. The blast2 sequence com-
parison program (NCBI) was used to compare the R. nor-
vegicus (NM_020093.1), M. musculus (AB019558.1) and
A. gambiae (XM316606.1) sequences individually with
the D. melanogaster parkin protein sequence [57]. The
multi-alignment of the five parkin homologues from D.
melanogaster, A. gambiae, R. norvegicus, M. musculus and H.
sapiens was constructed by editing the results from the
multialign ClustalW program from the Pôle Bio-Informa-
tique Lyonnaise [58,59].
Fly stocks and culture
Dr. M. Feany (Harvard Medical School) and Dr. J. Hirsh
(University of Virginia) generously provided UAS-α-synu-
clein [32] and Ddc-Gal44.36 flies [60] respectively. The
GMR-Gal4 flies [61] were obtained from the Bloomington
Drosophila Stock Center at Indiana University. A BglII/
XhoI fragment containing the parkin cDNA (SD01679)
was subcloned into the pUAST vector to generate the UAS-
parkin transgene. Two independent transgenic lines were
generated using heat shock π as a source of transposase
and standard injection techniques into w1118 embryos.
Double transgenic lines with UAS-α-synuclein;UAS-
parkin1.1 and UAS-α-synuclein;UAS-parkin2.1 were gener-
ated using standard techniques. To drive expression of the
transgenes, Ddc-Gal4 (for expression in the dopaminergic
neurons) or GMR-Gal4 (for expression in the eye)
homozygous females were crossed to w1118 males (con-
trol) or UAS-α-synuclein with or without UAS-parkin1.1 or
UAS-parkin2.1. All flies were cultured on standard corn-
meal/yeast/molasses/agar media at 25°C.
In situ hybridization analysis
Third instar larvae were dissected in PBS, fixed in 4% for-
maldehyde and dehydrated in methanol and ethanol. The
carcases were probed with a DIG labelled anti-sense parkin
RNA probe generated from a linear cut plasmid contain-
ing the entire parkin cDNA using the Roche Applied Sci-
ence DIG Northern starter kit and reduced in size with
carbonate buffer treatment. To visualize parkin RNA alka-
line phosphatase labelled anti-DIG anti-bodies were incu-
bated with the carcases and subjected to alkaline
phosphate treatment as per the Roche Applied Science
DIG application manual. The eye discs were dissected out
completely and examined under light microscopy. The
genotypes of the larvae examined were 1) w1118; 2) w1118;
GMR-Gal4/+; UAS-parkin1.1/+; and 3) w1118; GMR-Gal4/+;
UAS-parkin2.1/+ and at least ten of each genotype were
examined.
Aging analysis
Adult males were collected under gaseous carbon dioxide
anaesthetic and aged in small groups (~10 or less per vial)
upon standard cornmeal/yeast/molasses/agar media at
25°C in upright standard plastic shell vials. The flies were
scored for viability every two to three days and transferred
to fresh media without anaesthesia [62]. The numbers of
individuals aged are as follows: UAS-α-synuclein/+; Ddc-Page 10 of 12
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= 292; UAS-α-synuclein/+; UAS-parkin1.1/Ddc-Gal4 = 204;
w1118; Ddc-Gal4/+ = 173; UAS-parkin1.1/Ddc-Gal4 = 262;
and UAS-parkin2.1/Ddc-Gal4 = 227.
Locomotion assay
Flies were assayed for their ability to climb as described by
Feany and Bender [32]. Every five days, forty male flies
from a cohort of flies were assayed for their ability to
climb six centimetres in eighteen seconds in a sterile plas-
tic vial. Twenty trials were carried out for each time point.
Data shown represent the results from flies tested over
ninety days.
Scanning electron microscopy of the Drosophila eye
Flies were of each genotype [1) w1118; UAS-α-synuclein/
GMR-Gal4; 2) w1118; UAS-α-synuclein/GMR-Gal4; UAS-
parkin1.1/+; and 3) w1118; UAS-α-synuclein/GMR-Gal4;
UAS-parkin2.1/+] aged and frozen in a -70°C ethanol bath.
Whole flies were mounted, desiccated overnight and
coated in gold before photography at 150 times magnifi-
cation with a Hitachi S-570 SEM as per standard methods.
For each condition at least six flies were analysed.
Histological examination of Drosophila adult retinas
Adult flies [1) w1118; UAS-α-synuclein/GMR-Gal4; 2) w1118;
UAS-α-synuclein/GMR-Gal4; UAS-parkin1.1/+; and 3) w1118;
UAS-α-synuclein/GMR-Gal4; UAS-parkin2.1/+] were aged
(one or thirty days after eclosion), fixed in Karnovsky's fix-
ative and embedded in epon. Tangential retinal sections
were prepared at a thickness of 0.5 µm and stained with
toluidine blue, examined by light microscopy and photo-
graphed at magnification of 800 times.
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